denise
Share:
Compounding Pharmacies Market Growth Fueled by Personalized Medicine
What does the compounding pharmacies market growth mean for Pharma Marketers? The global compounding pharmacies market is expanding quickly, with FMI projecting growth from USD 14.0 billion in 2026 to USD 29.2 billion by 2036 at a 7.6% CAGR. The main driver is the rising demand for personalized medicine and patient-specific treatment options, especially when commercially available drugs do not fully meet clinical needs.
Several practical growth signals include: oral compounded medications lead the market, adult patient use is the largest application segment, and the United States remains one of the strongest growth markets. The piece notes that competition is centered on formulation capability, quality assurance, prescription responsiveness, and compliance, while regulatory complexity and pricing pressure remain ongoing constraints.
Responsory’s takeaway: For pharma and medical brands, the opportunity is not just market growth; it is positioning around precision, access, and clinical relevance. The brands that win in this space will be the ones that communicate clear value to prescribers and patients while staying tightly aligned with quality and regulatory expectations.
Get Your Copy of the Tiny Book of Big Results: Pharmaceutical Marketing Edition
A companion to the 2026 Tiny Book of Big Results, this edition distills the complexity of pharmaceutical marketing into 25 focused, industry-specific principles. Designed for marketers navigating the intersection of compliance, commercialization, and growth, it delivers practical insights you can apply immediately. Inside, you’ll discover:- How to elevate HCP engagement in a crowded, regulated landscape
- Why audience insight—not channel selection—drives meaningful impact
- The most common launch pitfalls and how to avoid them
- How leading pharma brands build and sustain market momentum
- Real-world lessons drawn from successful pharmaceutical marketing programs
Schedule a 30-minute exploratory session, and we’ll send up to 10 complimentary booklets of the Tiny Book of Big Results: Pharmaceutical Marketing Edition—an easy, practical resource your team can use for ongoing inspiration.
Prescription Drug Affordability: Examining Select Price Drivers
Prescription drug affordability is shaped by more than just list price. In this brief, the Bipartisan Policy Center looks at how pricing strategies, competition, and market dynamics influence what patients ultimately pay, while noting that higher drug spending can sometimes be offset by better adherence and fewer downstream medical costs. The article also highlights a shift toward more specialty, biologic, and orphan drugs, which are often launched at higher prices and face fewer competitors. It underscores how generics and biosimilars can help reduce costs, but that patent disputes, rebate structures, and other market barriers can slow that impact. Responsory’s takeaway: Drug affordability is no longer just a pricing issue; it’s a market access and value story. For pharma marketers, the challenge is to communicate clinical and economic value clearly enough to support coverage, preserve trust, and differentiate the brand in a more cost-conscious environment.
Trend Report Analysis: How Pharma Leaders Can Optimize for AI Adoption
The 2026 Market Research Trends Report highlights a fundamental shift from AI adoption to AI orchestration, where competitive advantage is driven by how effectively organizations integrate AI across the research lifecycle. AI agents are democratizing access to insights, enabling stakeholders beyond research teams to self-serve data and accelerate decision-making. At the same time, leading organizations are moving away from fragmented, general-purpose tools toward purpose-built platforms that unify data, analysis, and insight generation. The rise of synthetic data is further expanding what research can achieve allowing teams to test more ideas earlier, reduce costs, and increase speed. Organizations that fail to evolve risk losing strategic influence and budget. Responsory’s takeaway: Pharmaceutical organizations must reposition insights as a strategic growth driver, not a support function. This means enabling commercial, marketing, and medical teams with faster, self-service access to insights, while elevating research teams into strategic partners who guide high-impact decisions like launch planning and brand positioning.
Patient-Centered Content Is the Next Pharma Brand Differentiator
Today’s patients arrive at appointments armed with research, questions, and high expectations — and physicians are pressed for time, looking for credible resources they can hand off without a second thought. This Responsory article makes the case for evidence-based educational content as a strategic differentiator: one that serves both audiences simultaneously, drives medication adherence, builds physician confidence, and positions your brand as a trusted partner in practice. From in-office posters and downloadable guides to digital touchpoints that generate measurable analytics, the article shows how a single well-crafted asset can work across the full omnichannel journey. Responsory’s takeaway: Pharma brands that stop selling and start serving — through content grounded in science, shaped by empathy and distributed across the right channels — will build the kind of trust that translates into lasting HCP relationships and better patient outcomes.
🖥️The Challenges Pharma Faces When Marketing DTC
DTC pharma advertising is under pressure from multiple directions: tightening regulations under the Trump Administration, eroding consumer trust, and the rise of precision digital targeting. And, the industry is being forced to rethink its playbook. In this Pharmaceutical Executive video interview, Impiricus co-founder Sandy Donaldson lays out where DTC is headed and what it means for how pharma reaches both consumers and physicians. Responsory’s takeaway: The era of mass DTC TV is giving way to something more targeted, more digital, and more physician-centric. Smart marketers won’t just adapt to the regulatory constraints — they’ll get ahead of the shift by doubling down on HCP education, disease awareness campaigns, and precision digital engagement that builds trust rather than backlash.
Biosimilars Are Entering a New Regulatory Inflection Point
This Advisory explains the requirements a sponsor must meet to get a biosimilar approved, the difference between biosimilars and interchangeable biosimilars, and how these differ from generic drugs under U.S. law. As biologic drugs continue to account for a growing share of healthcare spend, biosimilars are poised to become a major commercial and strategic force — but not through incremental change. Regulatory evolution in the U.S. is reshaping how these complex medicines are developed, approved, and ultimately marketed. The latest guidance from the FDA, and the implications that flow from it, signal a genuine inflection point for biosimilar commercialization. Responsory’s takeaway: These regulatory shifts don’t just affect CMC or regulatory affairs, they ripple through commercial playbooks: 1. Competitive dynamics will accelerate; 2. Interchangeability may no longer be a slog; 3. Education becomes a strategic priority; and 4. Launch timing matters more than ever.
Recap of J.P. Morgan’s Jan ’26 Healthcare Conference
The 2026 J.P. Morgan Healthcare Conference highlighted a cautiously optimistic healthcare outlook marked by rising deal activity, innovation momentum, and shifting competitive dynamics. Leaders at the event emphasized technology’s expanding role—especially AI and digital tools across discovery, clinical development, and care delivery—alongside ongoing strategic responses to global market pressures and patent-cliff challenges. China’s growing influence in biotech, accelerated collaborations between technology and pharma companies, and a strong pipeline of new modalities further underscored how capital markets, regulatory clarity, and operational priorities are shaping the sector’s trajectory in 2026. Sentiment at the conference reflected a transition from uncertainty toward execution, with dealmaking, innovation focus, and cross-sector partnerships emerging as central themes for the year ahead. Responsory’s takeaway: For commercial and marketing leaders in pharma and life sciences, JPM 2026’s discussions signal a strategic inflection point where technology adoption, data-driven innovation, and market dynamics are converging to reshape competitive playbooks. Marketers should anticipate 1) accelerated product and technology launches, 2) heightened emphasis on differentiated value propositions (particularly around AI-enabled capabilities and emerging modalities), and 3) the need to align messaging with evolving investment, regulatory, and partnership priorities shaping healthcare’s commercial landscape in 2026 and beyond.
Pharma Marketing Trends: Embracing Digital Transformation and a Patient-Centric Approach
In this Q&A, pharmaceutical executive, Katrina Rice, discusses how the industry is navigating a shift in Diversity, Equity, and Inclusion (DE&I) strategies following administrative and regulatory changes. Rather than treating DE&I as a standalone initiative, companies are increasingly embedding these principles into core business operations, particularly within clinical trial recruitment and community partnerships to ensure long-term health equity. Moving into 2026, the industry is expected to rely more heavily on data analytics to measure the success of fair representation in both research and leadership. Responsory’s takeaway: This operational shift isn’t just ethical; it’s a competitive advantage. Companies that integrate equity into their business strategy will differentiate themselves through stronger innovation, patient trust, and market resilience in an uncertain regulatory landscape.
10 Healthcare Industry Predictions For 2026
A tumultuous 2026 is predicted for the U.S. healthcare industry as rising public discontent over costs sparks a period of significant revolution. Key shifts include the mainstreaming of wellness movements and the evolution of AI from experimental hype toward integrated growth engines, though implementation challenges remain. Meanwhile, pharmaceutical companies face intense scrutiny over drug pricing and PBM transparency while simultaneously navigating a more complex global regulatory landscape. Responsory’s takeaway: Leaders who understand the intersection of consumer anger, technological disruption, and regulatory pressure will be positioned to navigate consolidation, protect market position, and potentially emerge as “quiet heroes.”
